113. Pre-Travel Assessment of Measles Immunity Status and Administration of MMR for Adult International Travelers seen in Global TravEpiNet Sites
Session: Oral Abstract Session: Global Health
Thursday, October 8, 2015: 11:00 AM
Room: 32--ABC

Background: Measles outbreaks persist in the United States (US) because of imported cases, most of which are due to returning US travelers infected abroad. We sought to determine the measles immunity status of departing US travelers seeking pre-travel advice and reasons for non-vaccination among the vaccine-eligible.

Methods: We used data collected during pre-travel consultations (2009-2014) from 24 sites associated with Global TravEpiNet (GTEN), a Centers for Disease Control and Prevention (CDC)-sponsored consortium. We used provider-collected data regarding itineraries, travelers' medical conditions, and vaccination histories. We defined measles immunity as a positive serology, history of 2 measles-mumps-rubella (MMR) vaccinations, or self-reported prior measles illness. Providers could indicate immunity without a specific reason (“Immune not otherwise specified”). We defined travelers who did not meet criteria for immunity or medical exemption as “vaccine-eligible,” for whom CDC guidelines recommend pre-travel MMR vaccination. If MMR was not administered, providers selected a rationale from a list of possibilities. Analyses were conducted using SAS, version 9.2 (SAS Institute Inc., Cary, NC).

Results: Of 40,817 adult travelers born ≥1957, 7,181 (18%) were vaccine-eligible, of whom 44% were vaccinated (Figure 1). Non-vaccination was due to provider or patient decision (52% vs 48%, respectively). Providers most frequently deemed the vaccination “not indicated” or referred the patient to a primary care provider (PCP); patients frequently refused vaccination because they were “not concerned about illness.”

Conclusion: Eighteen percent of US adult travelers who presented at GTEN sites merited MMR vaccination, but fewer than half of them were vaccinated at the pre-travel consultation. Our estimates could under-represent the opportunities for vaccination, as providers often did not require formal documentation of measles vaccination and accepted verbal history of disease and non-specified determinations of immunity. To reduce measles importations, patients and providers need further education regarding measles risk that emphasizes the importance of vaccinating non-immune travelers prior to departure.

Emily Hyle, MD1, Sowmya Rao, PhD2, Emily Jentes, PhD, MPH3, Amy Parker Fiebelkorn, MSN, MPH4, Stefan Hagmann, MD5, Rochelle Walensky, MD MPH1, Edward Ryan, MD1 and Regina Larocque, MD, MPH, FIDSA1, (1)Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, (2)Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, (3)Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, (4)Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (5)Bronx Lebanon Hospital Center, Division of Pediatric Infectious Diseases, Bronx, NY

Disclosures:

E. Hyle, None

S. Rao, None

E. Jentes, None

A. P. Fiebelkorn, None

S. Hagmann, None

R. Walensky, None

E. Ryan, None

R. Larocque, None

See more of: Global Health
See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.